Trinity Operating Profit Margin from 2010 to 2024

TRIB Stock  USD 1.12  0.01  0.88%   
Trinity Biotech's Operating Profit Margin is increasing over the years with very volatile fluctuation. Overall, Operating Profit Margin is projected to go to -0.45 this year. From 2010 to 2024 Trinity Biotech Operating Profit Margin quarterly data regression line had arithmetic mean of (0.09) and r-squared of  0.01. View All Fundamentals
 
Operating Profit Margin  
First Reported
2010-12-31
Previous Quarter
(0.48)
Current Value
(0.45)
Quarterly Volatility
0.50823909
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Trinity Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Trinity Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Total Revenue of 78.6 M or Gross Profit of 35.1 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0095 or Days Sales Outstanding of 88.98. Trinity financial statements analysis is a perfect complement when working with Trinity Biotech Valuation or Volatility modules.
  
Check out the analysis of Trinity Biotech Correlation against competitors.

Latest Trinity Biotech's Operating Profit Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Trinity Biotech plc over the last few years. It is Trinity Biotech's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Trinity Biotech's overall financial position and show how it may be relating to other accounts over time.
Operating Profit Margin10 Years Trend
Very volatile
   Operating Profit Margin   
       Timeline  

Trinity Operating Profit Margin Regression Statistics

Arithmetic Mean(0.09)
Geometric Mean0.15
Coefficient Of Variation(542.15)
Mean Deviation0.33
Median0.08
Standard Deviation0.51
Sample Variance0.26
Range1.958
R-Value0.09
Mean Square Error0.28
R-Squared0.01
Significance0.76
Slope0.01
Total Sum of Squares3.62

Trinity Operating Profit Margin History

2024 -0.45
2023 -0.48
2022 -0.15
2021 0.14
2020 0.19
2019 0.009642
2018 0.034

About Trinity Biotech Financial Statements

Trinity Biotech stakeholders use historical fundamental indicators, such as Trinity Biotech's Operating Profit Margin, to determine how well the company is positioned to perform in the future. Although Trinity Biotech investors may analyze each financial statement separately, they are all interrelated. For example, changes in Trinity Biotech's assets and liabilities are reflected in the revenues and expenses on Trinity Biotech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Trinity Biotech plc. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Profit Margin(0.48)(0.45)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:
Check out the analysis of Trinity Biotech Correlation against competitors.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Earnings Share
(2.25)
Revenue Per Share
6.968
Quarterly Revenue Growth
0.14
Return On Assets
(0.1)
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.